JP2017533928A5 - - Google Patents

Info

Publication number

JP2017533928A5

JP2017533928A5 JP2017525587A JP2017525587A JP2017533928A5 JP 2017533928 A5 JP2017533928 A5 JP 2017533928A5 JP 2017525587 A JP2017525587 A JP 2017525587A JP 2017525587 A JP2017525587 A JP 2017525587A JP 2017533928 A5 JP2017533928 A5 JP 2017533928A5

Authority

JP

Japan

Prior art keywords

pharmaceutically acceptable

compound

organ

alkyl

medicament according

Prior art date

2015-11-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 68
• 150000003839 salts Chemical class 0.000 claims description 55
• 210000000056 organ Anatomy 0.000 claims description 47
• 239000003814 drug Substances 0.000 claims description 29
• 210000001519 tissue Anatomy 0.000 claims description 20
• 239000003550 marker Substances 0.000 claims description 13
• 210000003491 skin Anatomy 0.000 claims description 13
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 10
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 10
• 230000017423 tissue regeneration Effects 0.000 claims description 9
• 210000000845 cartilage Anatomy 0.000 claims description 8
• 210000002216 heart Anatomy 0.000 claims description 8
• 210000000936 intestine Anatomy 0.000 claims description 8
• 210000004185 liver Anatomy 0.000 claims description 8
• 210000004072 lung Anatomy 0.000 claims description 8
• 210000003205 muscle Anatomy 0.000 claims description 8
• 210000002784 stomach Anatomy 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 210000004027 cell Anatomy 0.000 claims description 6
• 210000003734 kidney Anatomy 0.000 claims description 6
• 230000032683 aging Effects 0.000 claims description 5
• 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 5
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 5
• 230000003712 anti-aging effect Effects 0.000 claims description 5
• 238000004113 cell culture Methods 0.000 claims description 5
• 230000004936 stimulating effect Effects 0.000 claims description 5
• 230000008467 tissue growth Effects 0.000 claims description 5
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
• 102000005741 Metalloproteases Human genes 0.000 claims description 4
• 108010006035 Metalloproteases Proteins 0.000 claims description 4
• 229940079593 drug Drugs 0.000 claims description 4
• 239000003102 growth factor Substances 0.000 claims description 4
• 229910052708 sodium Inorganic materials 0.000 claims description 4
• 239000011734 sodium Substances 0.000 claims description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
• 239000011575 calcium Substances 0.000 claims description 2
• 229910052791 calcium Inorganic materials 0.000 claims description 2
• 229910052802 copper Inorganic materials 0.000 claims description 2
• 239000010949 copper Substances 0.000 claims description 2
• 229910052742 iron Inorganic materials 0.000 claims description 2
• 229910052744 lithium Inorganic materials 0.000 claims description 2
• 239000011777 magnesium Substances 0.000 claims description 2
• 229910052749 magnesium Inorganic materials 0.000 claims description 2
• WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
• 229910052751 metal Inorganic materials 0.000 claims description 2
• 239000002184 metal Substances 0.000 claims description 2
• 229910052700 potassium Inorganic materials 0.000 claims description 2
• 239000011591 potassium Substances 0.000 claims description 2
• 239000011701 zinc Substances 0.000 claims description 2
• 229910052725 zinc Inorganic materials 0.000 claims description 2
• 230000008520 organization Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 29
• 230000001737 promoting effect Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000029663 wound healing Effects 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 3
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000000126 substance Substances 0.000 description 1